Breast, lung, colon and rectum, prostate, skin, and stomach cancer were very common in this region. According to the WHO data, ~1.20 million of the new cases reported in 2020 were skin cancer cases. Skin cancer is by far the most common of all cancer types. Melanoma and non-melanoma are the two types of skin cancer. Although melanoma accounts for ~1% of total skin cancer cases, it causes maximum skin cancer deaths. The incidence rate of melanoma rapidly increased in the past few decades, and it also varies with age. According to the American Cancer Society, the US's annual new cancer diagnoses count is likely to reach ~99,780 cases in 2022; out of these, 57,180 patients are likely to be men, and 42,600 would be women. It further states that 7,650 people are expected to die due to melanoma (5,080 men and 2,570 women). According to the Skin Cancer Foundation, during 2012–2022, annual diagnosis for invasive melanoma cases increased by 31%. Thus, the incidence of skin cancer is likely to increase in the coming years leading to higher demand for skin cancer diagnostics.
With the new features and technologies, vendors attract new customers and expand their footprints in emerging markets. This factor is driving the growth of the skin cancer diagnostics market at a promising CAGR.
The skin cancer diagnostics market is segmented into type and screening type. Based on type, the market is segmented into melanoma and non-melanoma. Based on screening type, the market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests. Based on country, the market is segmented into the US, Canada, and Mexico.
SkylineDx BV; AMLo Biosciences Limited; DermLite LLC; bioMerieux SA; Veriskin Inc.; Castle Biosciences, Inc.; DermTech Inc.; F. Hoffmann-La Roche Ltd.; and Michelson Diagnostics Ltd. are among the leading companies in the North America skin cancer diagnostics market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,423.0 Million |
| Market Size by 2028 | US$ 2,354.2 Million |
| CAGR (2021 - 2028) | 7.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Skin Cancer Diagnostics Market is valued at US$ 1,423.0 Million in 2021, it is projected to reach US$ 2,354.2 Million by 2028.
As per our report North America Skin Cancer Diagnostics Market, the market size is valued at US$ 1,423.0 Million in 2021, projecting it to reach US$ 2,354.2 Million by 2028. This translates to a CAGR of approximately 7.5% during the forecast period.
The North America Skin Cancer Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Skin Cancer Diagnostics Market report:
The North America Skin Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Skin Cancer Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Skin Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Skin Cancer Diagnostics Market
